Cargando…
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
BACKGROUND: Both ganglioside GD2-targeted immunotherapy and antibody-drug conjugates (ADCs) have demonstrated clinical success as solid tumor therapies in recent years, yet no research has been carried out to develop anti-GD2 ADCs against solid tumors. This is the first study to analyze cytotoxic ac...
Autores principales: | Kalinovsky, Daniel V, Kibardin, Alexey V, Kholodenko, Irina V, Svirshchevskaya, Elena V, Doronin, Igor I, Konovalova, Mariya V, Grechikhina, Maria V, Rozov, Fedor N, Larin, Sergey S, Deyev, Sergey M, Kholodenko, Roman V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240879/ https://www.ncbi.nlm.nih.gov/pubmed/35764367 http://dx.doi.org/10.1136/jitc-2022-004646 |
Ejemplares similares
-
Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells
por: Kalinovsky, Daniel V., et al.
Publicado: (2023) -
Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment–Drug Conjugates Carrying Maytansinoids DM1 and DM4
por: Kalinovsky, Daniel V., et al.
Publicado: (2023) -
Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
por: V. Kholodenko, Irina, et al.
Publicado: (2019) -
Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
por: Kholodenko, Irina V., et al.
Publicado: (2018) -
RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype
por: Sorokin, Maxim, et al.
Publicado: (2020)